Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) – Research analysts at Zacks Research lowered their Q3 2023 earnings per share (EPS) estimates for Pediatrix Medical Group in a research note issued to investors on Tuesday, July 11th. Zacks Research analyst D. Chatterjee now expects that the company will earn $0.39 per share for the quarter, down from their prior forecast of $0.40. The consensus estimate for Pediatrix Medical Group’s current full-year earnings is $1.43 per share. Zacks Research also issued estimates for Pediatrix Medical Group’s FY2023 earnings at $1.39 EPS and Q4 2024 earnings at $0.45 EPS.
Pediatrix Medical Group (NYSE:MD – Get Free Report) last posted its quarterly earnings results on Tuesday, May 2nd. The company reported $0.20 earnings per share for the quarter, hitting the consensus estimate of $0.20. Pediatrix Medical Group had a return on equity of 13.85% and a net margin of 5.14%. The business had revenue of $491.01 million during the quarter, compared to the consensus estimate of $487.38 million.
Pediatrix Medical Group Stock Performance
MD opened at $13.73 on Thursday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 11.25, a PEG ratio of 2.42 and a beta of 1.74. The company has a fifty day moving average of $13.75 and a 200 day moving average of $14.56. Pediatrix Medical Group has a fifty-two week low of $12.84 and a fifty-two week high of $23.95.
Insiders Place Their Bets
In other news, CEO James D. Swift sold 13,193 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $14.14, for a total value of $186,549.02. Following the completion of the sale, the chief executive officer now directly owns 96,638 shares of the company’s stock, valued at approximately $1,366,461.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Mark S. Ordan sold 33,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $13.26, for a total transaction of $437,580.00. Following the transaction, the director now directly owns 147,923 shares in the company, valued at approximately $1,961,458.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James D. Swift sold 13,193 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $14.14, for a total transaction of $186,549.02. Following the completion of the sale, the chief executive officer now directly owns 96,638 shares of the company’s stock, valued at approximately $1,366,461.32. The disclosure for this sale can be found here. Insiders have sold 64,186 shares of company stock valued at $867,934 over the last ninety days. 2.00% of the stock is owned by insiders.
Institutional Investors Weigh In On Pediatrix Medical Group
Several hedge funds and other institutional investors have recently modified their holdings of MD. PNC Financial Services Group Inc. lifted its holdings in Pediatrix Medical Group by 10.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 22,466 shares of the company’s stock valued at $527,000 after buying an additional 2,081 shares in the last quarter. AlphaCrest Capital Management LLC purchased a new position in shares of Pediatrix Medical Group during the first quarter worth approximately $242,000. Natixis Advisors L.P. raised its stake in shares of Pediatrix Medical Group by 35.3% during the first quarter. Natixis Advisors L.P. now owns 19,578 shares of the company’s stock valued at $460,000 after acquiring an additional 5,107 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Pediatrix Medical Group by 831.3% in the first quarter. Acadian Asset Management LLC now owns 7,311 shares of the company’s stock valued at $171,000 after purchasing an additional 6,526 shares during the period. Finally, MetLife Investment Management LLC grew its stake in Pediatrix Medical Group by 56.5% in the first quarter. MetLife Investment Management LLC now owns 42,018 shares of the company’s stock worth $987,000 after purchasing an additional 15,170 shares in the last quarter. 99.49% of the stock is currently owned by hedge funds and other institutional investors.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Read More
- Five stocks we like better than Pediatrix Medical Group
- Delta Takes Flight: Double-Digit Upside In Sight
- Generac Powers Up as Summer Temperatures Rise
- 3 Reasons Why Rivian Can Continue To Surge Higher
- Despite Breaking Higher, Analysts Remain Cautious HP Inc.
- PepsiCo Can Soar To New Highs In The 2nd Half
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.jpg?v=20230511062707&h=45&w=95&zc=2){kind=logo}
